Dr. Michael Mina an assistant professor at Harvard’s T.H. Chan School of Public Health, is an expert on rapid tests to prevent the spread of the virus. T.H. Chan and a specialist in diagnostic tests, is a strong advocate of rapid tests to prevent the spread of the virus. H. Chan School of Public Health and a specialist in diagnostic tests is a strong advocate of rapid tests to stop the spread of the virus. Although the United States expects vaccines to fight the pandemic, experts believe an important way to control the virus and fully restore the economy would be to use cheap, quick paper strip tests to identify people susceptible to the spread of SID-19. If the tests are cheap enough, Mina said, people could be tested before they go to work, say two or three times a week, so they know when to stay home and not risk infecting their co-workers. That makes them less reliable for diagnosing VOCID-19 infection in someone who has been sick or carried the virus for some time, but expert testers say they are great as a screening tool, a way to detect and isolate infectious people before they can spread the virus. Mina said the amount requested by the United States would only be about 3,000 tests a day, far less than the millions of tests a day the United States would have to use for some time to prevent the virus from spreading. So far, the FDA has refused to approve other rapid OTC tests for domestic use because their results have not yet been accurate enough to meet agency standards for diagnostic tests. “I’m encouraged that the government is taking several steps to show that it will push for faster access to the tests, but I think we’re reviewing those tests now. The tests can be used at the entrance to stadiums, concerts and airports to identify infectious people who don’t know they are infectious because they don’t have any symptoms. In addition to the tests announced Friday, Slavitt said the U.S. will work with an Australian company called Ellume to provide 8.5 million tests to Americans by the end of the year. The success of this plan depends on the availability of a large number of rapid tests and their cost being low enough for regular use. Because the tests target the part of the coronavirus that does not change, they should continue to perform well in detecting new variants of the virus. 5of 2021 – The Biden administration has pledged to make a quick home test of VIDOC-19 available to more Americans. Two other tests, which give results at home but require a prescription, have already been approved. The tests use proteins embedded in the paper to detect and capture key parts of the virus. Regulators have been reluctant to approve these tests because they produce a higher rate of false negatives than reference PCR tests performed in the lab. If regulations were relaxed, the FDA could approve several of the new tests and make them available to Americans very quickly, Mina said.